Skip to main content

New owner for Envigo

Inotiv, a US CRO specialising in nonclinical and analytical drug discovery and development services, has reached an agreement to acquire research models and services Envigo. The cash and shares deal gives UK-headquartered Envigo an enterprise value of about $545 million, and the combined company one of around $1.2 billion.

First non-animal allergy testing strategy approved

The Organisation for Economic Co-operation & Development (OECD) has approved the world’s first toxicology testing strategy without animal testing. This can now be used to test for skin sensitisation and any products that pass can be placed on the market.

The strategy, which consists of three ‘alternative’ methods, was jointly developed and validated over ten years by BASF and Givaudan, in partnership with various companies and scientific institutions, notably IIVS. It is claimed to have better predictivity for human allergy risks than traditional animal testing.

Subscribe to testing